NeoBiocon
Pharmaceuticals - Dubai, Dubai, United Arab Emirates
NeoBiocon Details
NeoBiocon is one of the leading UAE's pharmaceutical company focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the GCC.Established in the year 2009 as a joint venture of Biocon, a global biotechnology company based in India headed by Dr. Kiran Mazumdar Shaw and the NMC group, UAE headed by Dr. B R Shetty.NeoBiocon focuses on unmet medical needs and offers novel therapies with affordable prices to the patients. Today we market more than 35 products in various therapeutic categories and ranked amongst top 20 Pharmaceutical companies of the UAE.Biocon has harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet. As an innovation-led organization focused on providing affordable access, Biocon has leveraged its inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including Monoclonal Antibodies (MAbs), rh-insulin and Insulin Analogs. NeoBiocon brings innovative and affordable medicines for many of the world's most challenging diseases. Through our prescription medicines, we work with healthcare professionals to deliver innovative health solutions to their patients.With strong foot in cardiovascular segment, NeoBiocon is No.1 generic company in the cardiovascular market of the UAE. The company has also solid presence in other segments like Diabetes, Oncology, anti- infectives, asthma & allergy management & gastric disorders to name a few. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs and partnerships.
